Chugai Pharmaceutical Co., Ltd. (CHGCY)
Stock Price Chart
Key Info
| Market Cap | 12.96B |
| Revenue (ttm) | 753.85B |
| Net Income (ttm) | 202.56B |
| Shares Out | 559.69M |
| EPS (ttm) | 2.85 |
| PE Ratio | 8.13 |
| Forward PE | 28.49 |
| Dividend | $0.24 |
| Dividend Yield | 1.04% |
Stock Quote
| Trading Day | November 27 |
| Last Price | $23.16 |
| Previous Close | $22.36 |
| Change ($) | 0.80 |
| Change (%) | 3.58% |
| Day's Open | 22.57 |
| Day's Range | 22.57 - 23.97 |
| Day's Volume | 17,644 |
| 52-Week Range | 12.853 - 28.43 |
More Stats
| Market Cap | 12.96B |
| Enterprise Value | n/a |
| Earnings Date (est) | n/a |
| Ex-Dividend Date | Jul 6, 2020 |
| Shares Outstanding | 559.69M |
| Float | n/a |
| EPS (basic) | n/a |
| EPS (diluted) | 2.85 |
| FCF / Share | n/a |
| Dividend | $0.24 |
| Dividend Yield | 1.04% |
| Earnings Yield | 12.31% |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | n/a |
| Short Ratio | n/a |
| Short % of Float | n/a |
| Beta | 0.61 |
| PE Ratio | 8.13 |
| Forward PE | 28.49 |
| P/FCF Ratio | n/a |
| PS Ratio | 0.02 |
| PB Ratio | 8.16 |
| Revenue | 753.85B |
| Operating Income | n/a |
| Net Income | 202.56B |
| Free Cash Flow | n/a |
| Net Cash | n/a |
| Net Cash / Share | n/a |
| Gross Margin | 55.73% |
| Operating Margin | n/a |
| Profit Margin | n/a |
| FCF Margin | n/a |
| ROA | 16.02% |
| ROE | 23.31% |
| ROIC | n/a |
Analyst Forecasts
Analyst Consensus: n/a
Financial Performance
Financial Overview
No financial data available for this stock yet.
Company Profile
Company Details
| Full Name | Chugai Pharmaceutical Co., Ltd. |
| Country | Japan |
| Employees | 7,394 |
| CEO | Tatsuro Kosaka |
Stock Information
| Ticker Symbol | CHGCY |
| Stock Exchange | US OTC |
| Sector | Healthcare |
| Industry | Drug Manufacturers—General |
| Unique Identifier | OTCMKTS: CHGCY |
Description
Chugai Pharmaceutical Company, together with its subsidiaries, engages in the research, development, manufacture, marketing, and distribution of prescription medicines in Japan and internationally. The company's products for oncology primarily include Avastin, Herceptin, Rituxan, Alecensa, Perjeta, Xeloda, Tarceva, Kadcyla, Zelboraf, Neutrogin, Tecentriq, and Gazyva; bone and joint diseases/autoimmune diseases comprise Actemra, Edirol, Suvenyl, and Bonviva; renal diseases consist of Mircera and Oxarol; and other diseases comprise Tamiflu, CellCept, Copegus, and Hemlibra. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group and Genentech; and co-development agreements with Taisho Pharmaceutical Co., Ltd. and Nippon Shinyaku Co., Ltd. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.